GlassScriptPhysician profile
Robin B Dale
NPI 1578594032
$12,402.06
in general payments reported to CMS, 2019-2025
47 companies · $2,603 in 2025
The $2,603 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,706 · 2020: $1,321 · 2021: $1,969 · 2022: $1,467 · 2023: $1,533 · 2024: $1,804 · 2025: $2,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,939.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,258.60 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $1,198.86 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,049.17 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $859.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $735.86 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $732.85 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $711.35 | 2019-2025 | Trintellix |
| Amarin Pharma, INC. | $590.10 | 2019-2022 | |
| Pfizer INC. | $529.05 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $496.51 | 2019-2023 | |
| Axsome Therapeutics, INC. | $487.70 | 2022-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $477.34 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $449.02 | 2020-2025 | Airsupra, Farxiga |
| Tolmar, INC. | $326.27 | 2023-2025 | Jatenzo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.71 | 2020-2025 | Xifaxan, Trulance |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Dale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.